AD 8240

Drug Profile

AD 8240

Latest Information Update: 20 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Pharmaceutical
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 20 Jun 2000 Discontinued-Preclinical for Peptic ulcer in Japan (Unknown route)
  • 20 Jun 2000 Discontinued-Preclinical for Reflux oesophagitis in Japan (Unknown route)
  • 15 Sep 1999 No-Development-Reported for Peptic ulcer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top